Advertisement
ACRV vs IMRX
Which Stock Would AI Choose? Acrivon Therapeutics (ACRV) vs. Immuneering Corporation (IMRX) Stock Comparison
Key Takeaways
- Both ACRV and IMRX are pre-revenue, clinical-stage oncology developers, but they sit at different stages of maturity: Acrivon remains mid-stage, while Immuneering has advanced into a pivotal Phase 3 program.
- Immuneering holds a meaningfully larger cash cushion (roughly $182.7 million, with runway into 2029) versus Acrivon (about $90 million, with runway into late 2027), a key contrast in financial durability.
- Both stocks carry concentrated binary event risk tied to clinical readouts; relative performance in recent weeks has been driven largely by data presentations and trial-milestone updates.
- Acrivon's value proposition centers on its AP3 proteomics platform and a broad pipeline, while Immuneering's is anchored on a single lead asset, atebimetinib, in first-line pancreatic cancer.
- Analyst sentiment is notably positive on Acrivon, with a consensus "Strong Buy" and price targets well above recent trading levels, while Immuneering has seen a mix of upgrades and a more cautious institutional stance.
- For more detail on each company's developments and daily action, explore ACRV Major News and ACRV Today's Price Move, as well as IMRX Major News and IMRX Today's Price Move.
- To see how algorithmic systems are currently positioning across these and thousands of other tickers, visit the curated Trending AI Robots page.
Introduction
Investors tracking small-cap biotechnology often weigh clinical momentum against balance-sheet strength. This stock comparison examines ACRV, Acrivon Therapeutics, and IMRX, Immuneering Corporation — two precision-oncology developers with no commercial revenue and market values that swing sharply on trial news. Both are pursuing differentiated cancer treatments and have delivered notable data updates in recent months, yet their market positioning differs substantially. This analysis is relevant for traders and investors focused on pre-revenue biotech, clinical catalysts, and relative performance, offering a fact-based view of how these two names compare across business model, momentum, risk, and sentiment.
ACRV Overview and Recent Performance
ACRV (Acrivon Therapeutics) is a clinical-stage biopharmaceutical company developing precision oncology medicines matched to patients using its proprietary AP3 proteomics platform. Its lead candidate, ACR-368 (prexasertib), is being studied in a registrational-intent Phase 2b trial in serous endometrial cancer, while ACR-2316, a dual WEE1/PKMYT1 inhibitor, is advancing through dose expansion in a Phase 1/2 study. In recent weeks, the company has emphasized upcoming catalysts, including a prespecified interim analysis for ACR-368 expected in the second half of the year.
On the financial side, Acrivon reported narrower net losses year over year and held roughly $90 million in cash, cash equivalents, and investments as of mid-year, with runway projected into the fourth quarter of 2027. The stock has traded in the low single digits, and recent market activity has been shaped by analyst coverage, with several firms maintaining Buy ratings and price targets well above the prevailing price. Sentiment appears supported by the breadth of the pipeline and data presentations, though the company remains several steps from commercialization.
IMRX Overview and Recent Performance
IMRX (Immuneering Corporation) is a late-stage clinical oncology company developing a new category of medicines it calls Deep Cyclic Inhibitors. Its lead asset, atebimetinib, is an oral, once-daily MEK inhibitor (MEK is a key enzyme in the MAPK signaling pathway, which is overactive in many cancers, including roughly 97% of pancreatic cancers). The company's pivotal Phase 3 trial, MAPKeeper 301, is now recruiting patients in first-line metastatic pancreatic cancer, with a topline readout expected in mid-2028.
Recent weeks have brought a steady cadence of data and updates. The company reported a 17.3-month median overall survival (the length of time half of patients remain alive) in a Phase 2a cohort of 55 first-line pancreatic cancer patients, alongside a favorable tolerability profile. Financially, Immuneering held approximately $182.7 million in cash and marketable securities at mid-year, with runway into 2029. The stock has been more volatile, and its relative performance has been influenced by cross-trial comparisons and the inherent uncertainty of an early-stage data set advancing toward a large registrational study.
Trending AI Robots
Tickeron operates hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, and performance profile. Because no single bot suits every market environment, Tickeron curates only the best-performing and most suitable strategies into its Trending AI Robots section. These featured bots vary widely in approach — from short-term momentum and swing strategies to longer-horizon trend systems — and cover different sets of tickers, including small-cap biotechnology names. The curation process is designed to surface bots aligned with current market conditions rather than simply listing every available strategy. For traders interested in seeing which algorithmic systems are currently favored across the market, reviewing the Trending AI Robots page can provide a useful, data-driven starting point.
Head-to-Head Comparison
Although both companies operate in oncology, their risk profiles diverge meaningfully. ACRV is a platform-driven, multi-asset story still in mid-stage trials, which offers pipeline breadth but also a longer and less certain path to a pivotal catalyst. IMRX is more advanced clinically but more concentrated, with its near-term thesis resting heavily on a single lead program in pancreatic cancer.
From a balance-sheet standpoint, IMRX holds roughly twice the cash of ACRV and a materially longer runway, reducing near-term dilution risk. In contrast, ACRV benefits from stronger sell-side conviction and insider buying, while IMRX has seen more mixed institutional positioning. On momentum, both have been event-driven, but IMRX faces the added pressure of investors scrutinizing cross-trial survival comparisons, whereas ACRV's catalysts are more distributed across its pipeline. Sector exposure is identical — biotechnology — but the concentration and maturity of each catalyst path are not.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely assign a modest edge to IMRX in the current environment. The company's larger cash balance, extended runway into 2029, and advancement into a pivotal Phase 3 trial offer a comparatively more stable and defined catalyst structure. That said, the verdict is probabilistic rather than definitive: ACRV's broader pipeline and stronger analyst conviction could translate into more favorable trend consistency if its upcoming interim data readouts land positively. The AI's preference would therefore hinge on weighting balance-sheet durability and clinical-stage maturity against pipeline breadth and sentiment momentum.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRV is a Hold and IMRX is a Buy.
Momentum Indicator for ACRV turns negative, indicating new downward trend
ACRV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 73 similar instances where the indicator turned negative. In 67 of the 73 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for ACRV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 30 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
ACRV moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ACRV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACRV entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACRV's RSI Indicator exited the oversold zone, 24 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.796) is normal, around the industry mean (3.498). P/E Ratio (-0.856) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ACRV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IMRX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
IMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 37 cases where IMRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMRX's RSI Oscillator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where IMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on IMRX as a result. In 80 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for IMRX just turned positive on October 20, 2026. Looking at past instances where IMRX's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Following a +7.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRX advanced for three days, in 220 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMRX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. IMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.248) is normal, around the industry mean (3.498). P/E Ratio (-3.957) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| ACRV | IMRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 86% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 89% | 8 days ago 88% |
| Declines ODDS (%) | 2 days ago 88% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ACRV’s FA Score shows that 0 FA rating(s) are green while IMRX’s FA Score has 1 green FA rating(s).
- ACRV’s FA Score: 0 green, 5 red.
- IMRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ACRV’s TA Score shows that 4 TA indicator(s) are bullish while IMRX’s TA Score has 6 bullish TA indicator(s).
- ACRV’s TA Score: 4 bullish, 6 bearish.
- IMRX’s TA Score: 6 bullish, 2 bearish.
Price Growth
ACRV (@Biotechnology) experienced а -5.99% price change this week, while IMRX (@Biotechnology) price change was +4.62% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
ACRV is expected to report earnings on Nov 12, 2026.
IMRX is expected to report earnings on Mar 11, 2027.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ACRV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ACRV has been loosely correlated with IMRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRV jumps, then IMRX could also see price increases.
| Ticker / NAME | Correlation To ACRV | 1D Price Change % | ||
|---|---|---|---|---|
| ACRV | 100% | -0.63% | ||
| IMRX - ACRV | 51% Loosely correlated | +5.48% | ||
| ALLR - ACRV | 48% Loosely correlated | -3.49% | ||
| CRMD - ACRV | 43% Loosely correlated | -1.83% | ||
| DNA - ACRV | 41% Loosely correlated | -2.91% | ||
| SANA - ACRV | 38% Loosely correlated | -1.42% | ||
More | ||||
IMRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMRX has been loosely correlated with ACRV. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRX jumps, then ACRV could also see price increases.
| Ticker / NAME | Correlation To IMRX | 1D Price Change % | ||
|---|---|---|---|---|
| IMRX | 100% | +5.48% | ||
| ACRV - IMRX | 52% Loosely correlated | -0.63% | ||
| CRMD - IMRX | 50% Loosely correlated | -1.83% | ||
| JSPR - IMRX | 40% Loosely correlated | -9.90% | ||
| LXEO - IMRX | 40% Loosely correlated | -2.55% | ||
| GHRS - IMRX | 39% Loosely correlated | +1.56% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IMF | 52.12 | 0.42 | +0.81% |
| Invesco Managed Futures Strategy ETF (IMF) | |||
| MAYC | 26.38 | N/A | N/A |
| Corgi U.S. Equities 10% Structured Buffer ETF (MAYC) | |||
| PPTY | 33.30 | -0.13 | -0.40% |
| US Diversified Real Estate ETF (PPTY) | |||
| VTWG | 258.74 | -2.21 | -0.85% |
| Vanguard Russell 2000 Growth ETF (VTWG) | |||
| BPRO | 18.84 | -0.52 | -2.69% |
| Bitwise Proficio Currency Debasement ETF (BPRO) | |||